Description

Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro[1].—Cancer-programmed cell death–C91H117N19O26—-[1]Jaszberenyi M, et al. Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget. 2013 Mar;4(3):422-32.–139570-93-7–1893.01—-OC1=C2C(C(C3=C(OC)C=CC=C3C2=O)=O)=C(O)C([C@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)=C1C[C@](O)(C4)C(COC(CCCC(NCCCC[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(NCC(N)=O)=O)=O)=O)=O)NC([C@@H](NC([C@H](CO)NC([C@@H](NC([C@@H](NC([C@H]7NC(CC7)=O)=O)CC8=CN=CN8)=O)CC9=CNC=CC=CC=C9)=O)=O)CC=CC=C(C=C)O)=O)=O)=O)=O–Cancer–H2O–GnRH Receptor—-GPCR/G Protein–Peptides